Finally, we utilized a tissue microarray (TMA) and immunohistochemistry to demonstrate that combined indexes of ANXA2 and GPC1 could improve the evaluation of prognosis in glioma patients. This evidence concerns the gene GPC1 and central nervous system cancer.